A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of the combination of JNJ-87189401 and JNJ-78278343 is, with or without apalutamide. Part 3 of this study evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with standard of care (SOC) lutetium Lu-177 vipivotide tetraxetan. Part 4 of this study further evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with JNJ-101556143 in participants with advanced prostate cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak prostaty typu gruczolakoraka (potwierdzony badaniem).
- •Choroba, którą można zmierzyć lub ocenić.
- •Pacjenci, którzy przeszli zabieg usunięcia jąder lub są poddawani terapii hormonalnej obniżającej poziom męskich hormonów.
- •Ogólny stan zdrowia pozwalający na aktywność fizyczną (grupa 0 lub 1 w skali ECOG).
✗ Disqualifies
- •Choroby autoimmunologiczne w ciągu ostatniego roku.
- •Zawał serca lub poważne problemy z sercem w ciągu ostatnich 6 miesięcy.
- •Przemijający atak niedokrwienny lub udar mózgu w ciągu ostatnich 6 miesięcy.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 6, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (16)
University of Colorado Anschutz Medical Campus
Aurora, United States
Emory University Winship Cancer Institute
Atlanta, United States
University Of Minnesota
Minneapolis, United States
START New Jersey
East Brunswick, United States
Herbert Irving Comprehensive Cancer Center Columbia University Medical Center
New York, United States
Oregon Health And Science University
Portland, United States
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, United States
Tennessee Oncology
Nashville, United States
MD Anderson Cancer Center
Houston, United States
South Texas Accelerated Research Therapeutics, LLC (START)
San Antonio, United States
Swedish Medical Center
Seattle, United States
Peter MacCallum Cancer Centre
Melbourne, Australia
Institut Bergonie
Bordeaux, France
Centre Leon Berard
Lyon, France
Institut Gustave Roussy
Villejuif, France
The Cancer Institute Hospital of JFCR
Tokyo, Japan
Trial contact
Study Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.